Ultimovacs ASA (OSL:ULTI) Price-to-Tangible-Book : 1.17 (As of Apr. 30, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Price-to-Tangible-Book?

As of today (2024-04-30), Ultimovacs ASA's share price is kr6.98. Ultimovacs ASA's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was kr5.99. Hence, Ultimovacs ASA's Price to Tangible Book Ratio of today is 1.17.

The historical rank and industry rank for Ultimovacs ASA's Price-to-Tangible-Book or its related term are showing as below:

OSL:ULTI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16 Med: 7.39 Max: 20.5
Current: 1.17

During the past 9 years, Ultimovacs ASA's highest Price to Tangible Book Ratio was 20.50. The lowest was 1.16. And the median was 7.39.

OSL:ULTI's Price-to-Tangible-Book is ranked better than
79.67% of 1220 companies
in the Biotechnology industry
Industry Median: 2.69 vs OSL:ULTI: 1.17

A closely related ratio is called PB Ratio. As of today, Ultimovacs ASA's share price is kr6.98. Ultimovacs ASA's Book Value per Sharefor the quarter that ended in Dec. 2023 was kr8.12. Hence, Ultimovacs ASA's P/B Ratio of today is 0.86.

Ultimovacs ASA Price-to-Tangible-Book Historical Data

The historical data trend for Ultimovacs ASA's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Price-to-Tangible-Book Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

2.89

6.21

7.39

9.93

20.50

Ultimovacs ASA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															9.93	11.22	8.53	13.44	20.50

Competitive Comparison of Ultimovacs ASA's Price-to-Tangible-Book

For the Biotechnology subindustry, Ultimovacs ASA's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ultimovacs ASA's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's Price-to-Tangible-Book falls into.

Ultimovacs ASA Price-to-Tangible-Book Calculation

Ultimovacs ASA's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	6.98	/	5.991
	=	1.17

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Ultimovacs ASA Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.